Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/26/2017
Baylor Research Institute
mi
from
Dallas, TX
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/26/2017
Baylor Research Institute
mi
from
Dallas, TX
Click here to add this to my saved trials
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/26/2017
St. Luke's Episcopal Hospital
mi
from
Houston, TX
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/26/2017
St. Luke's Episcopal Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/26/2017
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/26/2017
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
Click here to add this to my saved trials
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/26/2017
Aurora St. Luke's Medical Center
mi
from
Milwaukee, WI
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/26/2017
Aurora St. Luke's Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/26/2017
Stanford University
mi
from
Palo Alto, CA
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/26/2017
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/26/2017
Denver CyberKnife
mi
from
Lone Tree, CO
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/26/2017
Denver CyberKnife
mi
from
Lone Tree, CO
Click here to add this to my saved trials
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/26/2017
St. Louis University Hospital
mi
from
Saint Louis, MO
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/26/2017
St. Louis University Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/26/2017
Ruikang Hospital
mi
from
Nanning,
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/26/2017
Ruikang Hospital
mi
from
Nanning,
Click here to add this to my saved trials
Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan
Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan
Status: Enrolling
Updated:  6/26/2017
University of CA, Davis Cancer Center
mi
from
Sacramento, CA
Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan
Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan
Status: Enrolling
Updated: 6/26/2017
University of CA, Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated:  6/26/2017
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated: 6/26/2017
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated:  6/26/2017
Tunnell Cancer Center at Beebe Medical Center
mi
from
Lewes, DE
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated: 6/26/2017
Tunnell Cancer Center at Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated:  6/26/2017
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated: 6/26/2017
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated:  6/26/2017
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated: 6/26/2017
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated:  6/26/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated: 6/26/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated:  6/26/2017
Duke Cancer Institute
mi
from
Durham, NC
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated: 6/26/2017
Duke Cancer Institute
mi
from
Durham, NC
Click here to add this to my saved trials
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated:  6/26/2017
Miriam Hospital
mi
from
Providence, RI
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated: 6/26/2017
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated:  6/26/2017
Rhode Island Hospital Comprehensive Cancer Center
mi
from
Providence, RI
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated: 6/26/2017
Rhode Island Hospital Comprehensive Cancer Center
mi
from
Providence, RI
Click here to add this to my saved trials
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated:  6/26/2017
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated: 6/26/2017
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated:  6/26/2017
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated: 6/26/2017
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated:  6/26/2017
Union Hospital of Cecil County
mi
from
Elkton, MD
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)
Status: Enrolling
Updated: 6/26/2017
Union Hospital of Cecil County
mi
from
Elkton, MD
Click here to add this to my saved trials
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC
Status: Enrolling
Updated:  6/26/2017
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC
Status: Enrolling
Updated: 6/26/2017
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC
Status: Enrolling
Updated:  6/26/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC
Status: Enrolling
Updated: 6/26/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
Biologic Endpoints in the Annihilation of Metastases for Oligometastasis (BEAM ON)
Status: Enrolling
Updated:  6/26/2017
University of Chicago
mi
from
North Chicago, IL
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
Biologic Endpoints in the Annihilation of Metastases for Oligometastasis (BEAM ON)
Status: Enrolling
Updated: 6/26/2017
University of Chicago
mi
from
North Chicago, IL
Click here to add this to my saved trials
Studying Biomarkers in Tumor Tissue and Blood Samples From Patients With Small Cell Lung Cancer Registered on CALGB-140202
Genomics of Small Cell Lung Carcinoma
Status: Enrolling
Updated:  6/26/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Studying Biomarkers in Tumor Tissue and Blood Samples From Patients With Small Cell Lung Cancer Registered on CALGB-140202
Genomics of Small Cell Lung Carcinoma
Status: Enrolling
Updated: 6/26/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
A Phase 1B Study of B-701 in Combination With Pembrolizumab in Relapsed or Refractory Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract
Status: Enrolling
Updated:  6/26/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
A Phase 1B Study of B-701 in Combination With Pembrolizumab in Relapsed or Refractory Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract
Status: Enrolling
Updated: 6/26/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Optical Imaging of Skin Cancers for Margin Delineation of Non-Melanoma Skin Cancers
Evaluation of Optical Imaging for Margin Delineation of Non-Melanoma Skin Cancers
Status: Enrolling
Updated:  6/27/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Optical Imaging of Skin Cancers for Margin Delineation of Non-Melanoma Skin Cancers
Evaluation of Optical Imaging for Margin Delineation of Non-Melanoma Skin Cancers
Status: Enrolling
Updated: 6/27/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Use of Propranolol to Reduce FDG Uptake in Brown Adipose Tissue in Pediatric Cancer Patients PET Scans
Investigation of Propranolol Premedication to Reduce FDG Uptake in Brown Adipose Tissue on PET Scans of Pediatric Cancer Patients
Status: Enrolling
Updated:  6/27/2017
University of Kentucky DanceBlue Pediatric Hematology/Oncology Clinic
mi
from
Lexington, KY
Use of Propranolol to Reduce FDG Uptake in Brown Adipose Tissue in Pediatric Cancer Patients PET Scans
Investigation of Propranolol Premedication to Reduce FDG Uptake in Brown Adipose Tissue on PET Scans of Pediatric Cancer Patients
Status: Enrolling
Updated: 6/27/2017
University of Kentucky DanceBlue Pediatric Hematology/Oncology Clinic
mi
from
Lexington, KY
Click here to add this to my saved trials
The Patient-Perspective of Complications After Colon and Rectum Surgery: A Qualitative Analysis
The Patient-Perspective of Complications After Colon and Rectum Surgery: A Qualitative Analysis
Status: Enrolling
Updated:  6/28/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
The Patient-Perspective of Complications After Colon and Rectum Surgery: A Qualitative Analysis
The Patient-Perspective of Complications After Colon and Rectum Surgery: A Qualitative Analysis
Status: Enrolling
Updated: 6/28/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated:  6/29/2017
Alta Bates Comprehensive Cancer Center
mi
from
Berkeley, CA
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated: 6/29/2017
Alta Bates Comprehensive Cancer Center
mi
from
Berkeley, CA
Click here to add this to my saved trials
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated:  6/29/2017
South Orange County Medical Research
mi
from
Laguna Hills, CA
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated: 6/29/2017
South Orange County Medical Research
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated:  6/29/2017
University of Colorado Health Sciences Ctr.
mi
from
Aurora, CO
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated: 6/29/2017
University of Colorado Health Sciences Ctr.
mi
from
Aurora, CO
Click here to add this to my saved trials
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated:  6/29/2017
Oncology Specialists, SC
mi
from
Park Ridge, IL
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated: 6/29/2017
Oncology Specialists, SC
mi
from
Park Ridge, IL
Click here to add this to my saved trials
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated:  6/29/2017
Mount Sinai School of Medicine
mi
from
New York, NY
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated: 6/29/2017
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated:  6/29/2017
Univ of Rochester Medical Center
mi
from
Rochester, NY
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated: 6/29/2017
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated:  6/29/2017
McKay Urology
mi
from
Charlotte, NC
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated: 6/29/2017
McKay Urology
mi
from
Charlotte, NC
Click here to add this to my saved trials
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated:  6/29/2017
AKSM Clinical Research Group
mi
from
Columbus, OH
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated: 6/29/2017
AKSM Clinical Research Group
mi
from
Columbus, OH
Click here to add this to my saved trials
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated:  6/29/2017
Providence Medical Center
mi
from
Portland, OR
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated: 6/29/2017
Providence Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated:  6/29/2017
Oregon Health and Sciences University
mi
from
Portland, OR
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated: 6/29/2017
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated:  6/29/2017
Oregon Urology Institute
mi
from
Springfield, OR
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated: 6/29/2017
Oregon Urology Institute
mi
from
Springfield, OR
Click here to add this to my saved trials
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated:  6/29/2017
Urology Health Specialists - Bryn Mawr
mi
from
Bryn Mawr, PA
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated: 6/29/2017
Urology Health Specialists - Bryn Mawr
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated:  6/29/2017
Albert Einstein Medical Building
mi
from
Philadelphia, PA
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated: 6/29/2017
Albert Einstein Medical Building
mi
from
Philadelphia, PA
Click here to add this to my saved trials
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated:  6/29/2017
Bryn Mawr Urology Group
mi
from
Rosemont, PA
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated: 6/29/2017
Bryn Mawr Urology Group
mi
from
Rosemont, PA
Click here to add this to my saved trials
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated:  6/29/2017
University of Tennessee
mi
from
Memphis, TN
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated: 6/29/2017
University of Tennessee
mi
from
Memphis, TN
Click here to add this to my saved trials
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated:  6/29/2017
Urology of Virginia, PLLC
mi
from
Virginia Beach, VA
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated: 6/29/2017
Urology of Virginia, PLLC
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated:  6/29/2017
Virginia Mason Medical Center
mi
from
Seattle, WA
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated: 6/29/2017
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated:  6/29/2017
Swedish Medical Center
mi
from
Seattle, WA
PROvenge Treatment and Early Cancer Treatment
Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial
Status: Enrolling
Updated: 6/29/2017
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
Status: Enrolling
Updated:  7/5/2017
University of Southern California
mi
from
Los Angeles, CA
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
Status: Enrolling
Updated: 7/5/2017
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
Status: Enrolling
Updated:  7/5/2017
Cornell Weill Scholl of Medicine
mi
from
New York, NY
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
Status: Enrolling
Updated: 7/5/2017
Cornell Weill Scholl of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Female Cancer Patients' Preference For Sexual Health Interventions
A Pilot Study Surveying Female Cancer Patients' Preference For Sexual Health Interventions
Status: Enrolling
Updated:  7/5/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Female Cancer Patients' Preference For Sexual Health Interventions
A Pilot Study Surveying Female Cancer Patients' Preference For Sexual Health Interventions
Status: Enrolling
Updated: 7/5/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Phase II Neoadjuvant Trial With Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Status: Enrolling
Updated:  7/5/2017
Northwestern University
mi
from
Chicago, IL
Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Phase II Neoadjuvant Trial With Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Status: Enrolling
Updated: 7/5/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials